Media About Us


  • 11 January 2018

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Genentech, Syndax expand HDAC-PD-L1 combination pact

    Nick Paul Taylor / FierceBiotech

    Genentech and Syndax have expanded their exploration of the effects of combining HDAC and PD-L1 inhibitors. The new agreement clears the Roche subsidiary to test its Tecentriq in combination with Syndax’s entinostat in a subset of breast cancer patients.

  • 11 December 2017

    An Epic quest to detect cancer

    An Epic quest to detect cancer

    Bradley J. Fikes / The San-Diego Union Tribune

    Finding needles in a haystack is the life-and-death job of San Diego’s Epic Sciences. The needles are extremely rare cancer cells that hide among the millions of normal cells in the blood of cancer patients.

  • 23 October 2017

    Contract R&D market is developing in Russia

    Contract R&D market is developing in Russia

    GMP News

    NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.

  • 23 October 2017

    Russian pharmaceutical map has a new point of convergence

    Russian pharmaceutical map has a new point of convergence

    GMP News

    An interesting international pharmaceutical project has started in Russia. This project is a result of a convergence of interests of Rusnano, Russian state investment corporation, Domain Associates, an American venture capital foundation, and Pfizer, an American pharmaceutical corporation.  

  • 08 September 2017

    New 30-minute STI test allows just one clinic trip

    New 30-minute STI test allows just one clinic trip

    Helen Clark / Gears of Biz

    A new speedy test will mean that for the first time ever patients with common sexually-transmitted infections will be able to get their diagnosis and treatment in one clinical visit. The test works by placing a swab or a small amount of urine into a test cartridge, which is then inserted into the diagnostic machine, which has been designed by innovation firm Atlas Genetics Ltd.

  • 17 August 2017

    Prostate Cancer: Epic Sciences AR-V7 Test

    Prostate Cancer: Epic Sciences AR-V7 Test

    OncLive

    Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.

  • 29 June 2017

    Syndax Locks In To Tumor Escape

    Syndax Locks In To Tumor Escape

    Seeking Alpha

    Syndax (NASDAQ:SNDX) is a $315 million market cap company focused on developing a pipeline of innovative combination therapies for cancer. The company's lead product is Entinostat, which was granted Breakthrough Therapy Designation by FDA for its Phase 2b clinical trial in advanced hormone receptor positive (Estrogen Receptor positive, ER+) breast cancer. The impact of Breakthrough Therapy Designation on biotechnology stocks has been previously described here by Strong Bio and is worth a read. The company has a host of impressive partnerships for its clinical trials, including Merck (NYSE:MRK) for a combinatory non-small cell lung cancer (NSCLC) and melanoma therapy, Genentech/Roche (OTCQX:RHHBY) for triple-negative breast cancer (TNBC), and Pfizer (NYSE:PFE) and Merck in Germany for ovarian cancer.

  • 16 June 2017

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed

    The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

  • 15 June 2017

    OD reports practiceТs success with corneal inlay

    OD reports practiceТs success with corneal inlay

    Jeffrey M. Augustine, OD / Healio

    The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.

  • 05 June 2017

    The three factors crucial to effectiveness in healthcare

    The three factors crucial to effectiveness in healthcare

    SPIEF-2017. Panel discussion "The three factors crucial to effectiveness in healthcare". “The problem and task is to boost the system’s performance within the budget available for now. That does not mean the system needs no more money, that means spending must be efficient,” said Leonid Melamed, Chairman of the Board of Directors, Team Drive.